Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending December 12, 2013. The report details a specific share repurchase transaction executed in accordance with shareholder authority granted at the Annual General Meeting on May 1, 2013.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses exclusively on capital structure changes related to share buybacks.
- Shares Purchased: 279,000 Ordinary Shares of 25 pence each.
- Purchase Date: December 12, 2013.
- Price Range: Highest price paid was 1,576.00 pence per share; lowest price paid was 1,562.00 pence per share.
- Treasury Holdings (Settled): 515,330,909 shares (9.59% of total issued share capital).
- Treasury Holdings (Including Unsettled): 516,618,909 shares (10.64% of total voting rights).
- Shares in Issue (Excluding Treasury): 4,856,539,277 shares.
Material Changes
The primary material change reported is the reduction of outstanding shares through the purchase of 279,000 shares for treasury. This transaction increased the company's treasury holdings to represent 10.64% of total voting rights when including unsettled purchases.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, management commentary on operations, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities.
Investor Verification Checklist
- Verify the total number of shares held in treasury (515,330,909 settled) against the company's latest annual report.
- Confirm the percentage of total voting rights held in treasury (10.64% including unsettled shares).
- Check the current number of shares in issue (4,856,539,277) for compliance with Disclosure and Transparency Rules.
- Review the price paid per share (1,562.00 to 1,576.00 pence) relative to the market price on December 12, 2013.